Healthcare Industry News:  OrthoNeutrogena 

Biopharmaceuticals Licensing

 News Release - October 28, 2008

Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals

Medimetriks Adds CentanyŽ (mupirocin ointment, 2%) and Two New Brands to Dermatology and Podiatry Product Portfolio

FAIRFIELD, N.J., Oct. 28 -- (Healthcare Sales & Marketing Network) -- Medimetriks Pharmaceuticals announced today that the Company entered into a licensing agreement with Perrigo Company (Nasdaq: PRGO ) for the U.S. marketing rights to CentanyŽ Ointment and two prescription keratolytic brands. Patented through 2018, CentanyŽ represents an important step in Medimetriks' plan to commercialize patent-protected therapies for the Dermatology and Podiatry markets that offer important patient benefits. Medimetriks plans to launch CentanyŽ in early 2009, with the two additional products following shortly thereafter.

Previously marketed by Johnson & Johnson's OrthoNeutrogena professional division, CentanyŽ is indicated for the topical treatment of impetigo due to Straphylococcus aureus and Streptococcus pyogenes, and will compete in a topical antibiotic market that exceeds $150 million. CentanyŽ received a New Drug Approval in December of 2002 based in part on the unique properties of its vehicle, which offers important benefits over its competitors.

The two prescription keratolytic brands are urea-based therapies indicated for the treatment of severe dry skin. They are offered in delivery systems that are gaining wide acceptance in the Dermatology and Podiatry markets and are both patent pending. These new brands will compete in a skin softening market that approaches one million prescriptions annually.

"We are happy to have a partner that brings such a record of success in the branded pharmaceutical business," stated Sharon Kochan, Executive Vice President of Perrigo. "We believe the licensed products are in good hands given Medimetriks management's proven abilities in building a successful business in the Dermatology and Podiatry markets."

Medimetriks President and CEO, Bradley Glassman, commented, "We are pleased to add these prescription brands to our portfolio. Perrigo is known for developing high quality products and we believe these brands will benefit both our core Dermatology and Podiatry audiences and their patients."

CentanyŽ is contraindicated in individuals with a history of sensitivity reactions to any of its components. The following local adverse reactions have been reported in connection with the use of CentanyŽ: application site reactions and pruritus, each in 1% of patients; contact dermatitis and furunculosis, each in 0.7% of patients; and exfoliative dermatitis and rash, each in 0.3% of patients.

Please see full prescribing information.

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.


Source: Medimetriks Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.